Pregabalin Capsule
Product Images NDC 63629-8248

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8248). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298248)

Label for Pregabalin Capsules, USP 300 mg by Bryant Ranch Prepack showing NDC 63629-8248-1. The label includes dosage strength prominently in a red-bordered box, barcode, and states package contains 60 capsules. Storage instructions and repackager information are also present.*

FDA Label Image

Label (Lbl6362982482)

Label for Pregabalin 300 mg capsules by Bryant Ranch Prepack. The label indicates the product is an orange capsule, lot number 1523487, with a package size of 60 capsules. It compares to Lyrica 300 mg capsules by ScieGen Pharmaceuticals Inc. Storage instructions specify room temperature (20°-25°C). The label includes the NDC 63629-8248 and a bar code.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares different doses of Pregabalin (200 mg, 100 mg, 25 mg, each taken three times a day) and placebo. The vertical axis represents the percent of patients improved, and the horizontal axis shows the percent improvement in pain from baseline.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day against placebo, with Pregabalin consistently showing higher patient improvement percentages across various pain improvement levels.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

Line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 75 mg, 150 mg, and 300 mg taken twice a day, compared to placebo. The vertical axis measures the percent of patients improved, and the horizontal axis displays the percent improvement in pain from baseline. Lines represent different dosages and placebo for comparison.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows treatment response over a range of pain improvement percentages up to 100%, with Pregabalin 200 mg showing the highest improvement rates, followed by Pregabalin 100 mg and placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis represents percent improvement in pain, while the y-axis represents the percent of patients improved.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph showing responder rates (%) across different dosages of Pregabalin compared to placebo in two studies, Study E1 and Study E3. The X-axis lists doses including placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day, while the Y-axis shows responder rate percentages from 0% to 60%. Study E1 and Study E3 results are side by side, highlighting statistically significant increases in responder rates at higher doses compared to placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percent change from baseline against daily dose in mg/day. Four studies (E1 BD, E2 TID, E3 BD, E3 TID) are charted with distinct markers showing increasing seizure reduction with higher doses, accompanied by significant p-values. The graph compares placebo and various dosing regimens, highlighting statistical significance for the data points shown.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 800mg daily dose, 450mg daily dose, 300mg daily dose, and placebo, showing trends in patient improvement at various pain reduction levels.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve comparing Pregabalin and Placebo groups over 180 days. The y-axis shows the estimated percentage of subjects without LTR, and the x-axis shows days. The solid line represents Pregabalin, and the dashed line represents Placebo, illustrating differing percentages over time between the two groups.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing percent of subjects improved over a range of percent improvement from baseline to week 12 BOCF for Pregabalin 300 mg and placebo. The solid line represents Pregabalin and shows a higher percent of subjects improved compared to the dotted placebo line across the percent improvement scale.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved over various improvement levels from baseline to week 16 for Pregabalin versus placebo. The x-axis shows percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved, with Pregabalin represented by a solid line and placebo by a dashed line. Vertical reference lines mark the 30%, 50%, and 70% improvement thresholds.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A text panel presenting a formula for calculating creatinine clearance (CLcr). The formula accounts for patient age in years, weight in kilograms, serum creatinine concentration in mg/dL, and includes a multiplication factor for female patients. This panel provides a clinical calculation formula without additional context or instructions.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram showing the molecular structure of pregabalin. The diagram includes labeled functional groups such as a CO2H (carboxyl) group and an NH2 (amino) group, along with the carbon backbone and side chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.